1283 related articles for article (PubMed ID: 14607913)
41. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells.
Silk JD; Salio M; Reddy BG; Shepherd D; Gileadi U; Brown J; Masri SH; Polzella P; Ritter G; Besra GS; Jones EY; Schmidt RR; Cerundolo V
J Immunol; 2008 May; 180(10):6452-6. PubMed ID: 18453560
[TBL] [Abstract][Full Text] [Related]
42. Spleen-resident CD4+ and CD4- CD8α- dendritic cell subsets differ in their ability to prime invariant natural killer T lymphocytes.
Bialecki E; Macho Fernandez E; Ivanov S; Paget C; Fontaine J; Rodriguez F; Lebeau L; Ehret C; Frisch B; Trottein F; Faveeuw C
PLoS One; 2011; 6(10):e26919. PubMed ID: 22066016
[TBL] [Abstract][Full Text] [Related]
43. Plasticity of invariant NKT cell regulation of allergic airway disease is dependent on IFN-gamma production.
Matsuda H; Takeda K; Koya T; Okamoto M; Shiraishi Y; Miyahara N; Dakhama A; Matsuda JL; Gapin L; Gelfand EW
J Immunol; 2010 Jul; 185(1):253-62. PubMed ID: 20525882
[TBL] [Abstract][Full Text] [Related]
44. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.
Shimizu K; Goto A; Fukui M; Taniguchi M; Fujii S
J Immunol; 2007 Mar; 178(5):2853-61. PubMed ID: 17312129
[TBL] [Abstract][Full Text] [Related]
45. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.
Chang YJ; Huang JR; Tsai YC; Hung JT; Wu D; Fujio M; Wong CH; Yu AL
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10299-304. PubMed ID: 17566107
[TBL] [Abstract][Full Text] [Related]
46. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
[TBL] [Abstract][Full Text] [Related]
47. Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation.
Trobonjaca Z; Kröger A; Stober D; Leithäuser F; Möller P; Hauser H; Schirmbeck R; Reimann J
J Immunol; 2002 Apr; 168(8):3763-70. PubMed ID: 11937527
[TBL] [Abstract][Full Text] [Related]
48. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
Durgan K; Ali M; Warner P; Latchman YE
Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
[TBL] [Abstract][Full Text] [Related]
49. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
Krishnan L; Sad S; Patel GB; Sprott GD
J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
[TBL] [Abstract][Full Text] [Related]
50. Critical role for CD1d-restricted invariant NKT cells in stimulating intrahepatic CD8 T-cell responses to liver antigen.
Sprengers D; Sillé FC; Derkow K; Besra GS; Janssen HL; Schott E; Boes M
Gastroenterology; 2008 Jun; 134(7):2132-43. PubMed ID: 18549881
[TBL] [Abstract][Full Text] [Related]
51. A cell-type specific CD1d expression program modulates invariant NKT cell development and function.
Zimmer MI; Colmone A; Felio K; Xu H; Ma A; Wang CR
J Immunol; 2006 Feb; 176(3):1421-30. PubMed ID: 16424169
[TBL] [Abstract][Full Text] [Related]
52. Altered invariant natural killer T cell subsets and its functions in patients with oral squamous cell carcinoma.
Singh AK; Shukla NK; Das SN
Scand J Immunol; 2013 Nov; 78(5):468-77. PubMed ID: 23980793
[TBL] [Abstract][Full Text] [Related]
53. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.
Bontkes HJ; Moreno M; Hangalapura B; Lindenberg JJ; de Groot J; Lougheed S; van der Vliet HJ; van den Eertwegh AJ; de Gruijl TD; von Blomberg BM; Scheper RJ
Clin Immunol; 2010 Sep; 136(3):364-74. PubMed ID: 20570567
[TBL] [Abstract][Full Text] [Related]
54. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
55. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.
Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J
J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432
[TBL] [Abstract][Full Text] [Related]
56. H2-D(d)-mediated upregulation of interleukin-4 production by natural killer T-cell and dendritic cell interaction.
Mizuuchi K; Yanagawa Y; Iwabuchi K; Namba K; Kitaichi N; Ohno S; Onoé K
Immunology; 2008 May; 124(1):102-11. PubMed ID: 18194275
[TBL] [Abstract][Full Text] [Related]
57. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
58. Natural killer T cell activation inhibits hepatitis B virus replication in vivo.
Kakimi K; Guidotti LG; Koezuka Y; Chisari FV
J Exp Med; 2000 Oct; 192(7):921-30. PubMed ID: 11015434
[TBL] [Abstract][Full Text] [Related]
59. Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties.
Miller G; Pillarisetty VG; Shah AB; Lahrs S; DeMatteo RP
J Immunol; 2003 Apr; 170(7):3554-64. PubMed ID: 12646617
[TBL] [Abstract][Full Text] [Related]
60. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.
Singh N; Hong S; Scherer DC; Serizawa I; Burdin N; Kronenberg M; Koezuka Y; Van Kaer L
J Immunol; 1999 Sep; 163(5):2373-7. PubMed ID: 10452969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
